Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines중증급성호흡기증후군 코로나바이러스 2 벡터 및 mRNA 기반 백신 접종 후 3차 병원 직원 중 접종 후 감염Observational Study Published on 2022-04-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered administration Alpha variant analysed Antigen B.1.1.7 B.1.351 B.1.617.2 Beta Beta variant BNT162b2 Breakthrough infection breakthrough infections Care ChAdOx1 ChAdOx1-S cohort study coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 death defined Delta delta variant demographic data dose effective first dose follow-up period hazard ratio hazard ratios hospital Hospital employees Hospitalization incidence Infection mRNA mRNA-based vaccine mRNA-based vaccine. not differ Observational cohort study Participants positive PCR positive PCR test postvaccination Postvaccination infection reported respiratory specimen retrospective retrospective observational cohort study RNA SARS-CoV-2 SARS-CoV-2 vaccine second dose severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 specimen vaccination Vaccination Status Vaccine vaccine dose vaccine doses variant Vector-based vaccine Viral load virus variants [DOI] 10.1016/j.cmi.2021.11.023 PMC 바로가기 [Article Type] Observational Study
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination동종 ChAdOx1-nCoV-19 또는 동종 mRNA-1273 백신과 비교한 이종 ChAdOx1-nCoV-19/mRNA-1273 백신의 면역 반응 및 안전성Article Published on 2022-04-012022-09-11 Journal: Journal of the Formosan Medical Association = Taiw [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Adenovirus Adenovirus-vector vaccine Adverse adverse event adverse events AEs Alpha anti-SARS-CoV-2 IgG AstraZeneca B.1.1.7 B.1.617.2 ChAdOx1 ChAdOx1-nCoV-19 comparable coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 vaccines Efficacy enrolled event female four groups group Heterologous heterologous prime-boost homologous homologous or heterologous IgG titers immune response less median age messenger Messenger RNA vaccine Mild Moderna MOST mRNA mRNA-1273 Neutralizing antibody response Neutralizing antibody titer neutralizing antibody titers participant Primary outcome provided recruited RNA SARS-CoV-2 second dose serum Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) significantly higher Support vaccination vaccination schedule Vaccines variant Volunteer was done were recorded [DOI] 10.1016/j.jfma.2022.02.020 PMC 바로가기 [Article Type] Article
Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based studyCoronaVac, BNT162b2, ChAdOx1 COVID-19 백신 및 단일 추가 접종 후 SARS-CoV-2 anti-spike 수용체 결합 도메인 IgG 항체 반응의 비교: 전향적, 종단적 인구 기반 연구Article Published on 2022-04-012022-09-12 Journal: The Lancet. Microbe [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI addition age Anti-spike Anti-spike RBD IgG antibody antibody level Antibody Response Antibody titre antibody titres baseline characteristics blood sample BNT162b2 boost booster booster dose ChAdOx1 ChAdOx1 vaccines collected concentrations CoronaVac COVID-19 pandemic COVID-19 vaccines Cyprus distribution dose evaluated Follow-up General population geometric group health-care help high-risk population highest IgG IgG antibody individual inoculated Laboratory Longitudinal data Male sex of BNT162b2 offered Older Older age participant RBD Reactions Receptor binding domain recruited regimen repeated measure Responder response SARS-CoV-2 second dose significantly significantly increased titre vaccination Vaccination strategies Vaccine was done [DOI] 10.1016/S2666-5247(21)00305-0 PMC 바로가기 [Article Type] Article
SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys영국의 SARS-CoV-2 감염 및 백신 효과(REACT-1): 일련의 횡단면 무작위 커뮤니티 설문조사Article Published on 2022-04-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI adjusted Administered Adults age assessment B.1.617.2 BNT162b2 Breakthrough infection breakthrough infections ChAdOx1 ChAdOx1 nCoV-19 children commenced Community community transmission contributed COVID-19 epidemic COVID-19 vaccine CrI cross-sectional cross-sectional survey Data collection declined delta variant Department dose driving Effectiveness England General population highest household size increased risk individual individuals Infection less Mutation nose swab Older Oxford-AstraZeneca participant Pfizer-BioNTech positive Prevalence random reduce Reproduction number risk RT-PCR SARS-CoV-2 SARS-CoV-2 epidemic SARS-COV-2 infection SARS-CoV-2 transmission second dose sequenced single dose Spike protein Spread Swab swabs the spike protein vaccination vaccination rate vaccination rates Vaccine vaccines combined variant [DOI] 10.1016/S2213-2600(21)00542-7 PMC 바로가기 [Article Type] Article
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months6개월 후 백신 단독 또는 SARS-CoV-2 감염 + 백신(하이브리드 면역)에 의해 유도된 항체에 의한 오미크론(B.1.1.529) 변이체의 차선 중화Article Published on 2022-04-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Against Anti-RBD IgG antibody B.1.1.529 BBV152 Biotechnology ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine correlation Covaxin Covishield cross-sectional cross-sectional study demonstrated Department exhibited explain foundation four group four groups geometric mean geometric mean titre GMT group groups hybrid Hybrid immunity Immune escape Immunity inactivated India individual Infection limit Live virus Live-virus neutralisation Melinda Gate Melinda Gates moderate natural infection nCoV neutralisation neutralisation assay neutralisation test neutralisation titre Neutralisation titres neutralise neutralising ability omicron Omicron variant outcome Primary outcome quantification Rapid reduction reduction in SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain SARS-CoV-2 variant serum Significant Spread subjects tested titre USA vaccinated individual vaccinated individuals vaccination Vaccine variant virus Virus neutralisation [DOI] 10.1016/j.ebiom.2022.103938 PMC 바로가기 [Article Type] Article
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses인도 델타(B.1.617.2) 변이형 급증 시 SARS-CoV-2 감염에 대한 ChAdOx1 nCoV-19 백신의 효과: 테스트 음성, 사례 대조군 연구 및 백신 접종 후 면역 반응에 대한 기계론적 연구Article Published on 2022-04-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 치료법, [키워드] 95% CI addition adjusted Alpha antibody Antigen B.1.1.7 B.1.351 B.1.617.1 B.1.617.2 Beta Biotechnology case-control study CD4 CD8 T-cell response CD8 T-cell responses cellular Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Complete conserved Control Council COVID-19 COVID-19 vaccine delta variant Department disease effective Effectiveness geometric mean geometric mean titre healthy Humoral immunity immune protection immune response immune responses In-vitro India individual Industrial infected individuals laboratory-confirmed SARS-CoV-2 infection Mild Mild disease moderate-to-severe COVID-19 negative RT-PCR neutralisation neutralising antibody neutralising antibody response Neutralising antibody responses participant PCR test positive RT-PCR Primary outcome recipient remained Research RT-PCR test SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants secondary outcome Secondary outcomes single dose Spike protein Spike-specific T-cell responses T-cell immune response T-cell immune responses T-cell Response tested the spike protein vaccinated individuals vaccination Vaccine variant variant of SARS-CoV-2 variants VoC VOCs wild-type SARS-CoV-2 with mild disease [DOI] 10.1016/S1473-3099(21)00680-0 PMC 바로가기 [Article Type] Article
Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age18~70세 심장 이식 환자의 SARS-CoV-2 아데노바이러스 벡터 백신 접종(ChAdOx1 nCoV-19[AZD1222])에 대한 체액 반응Article Published on 2022-04-012022-09-11 Journal: The Journal of heart and lung transplantation : th [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] 95% CI Adenovirus adenovirus vector vaccine adenovirus vector vaccines administration adverse event age antibody Antibody Response binding domain ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine chronic Chronic kidney disease CKD Concentration detectable develop domain dose enrolled fatigue female headache heart heart transplant help Humoral response immune response immunogenicity Immunosuppressed immunosuppressed patients injection site pain Kidney disease less Messenger RNA minor symptom minor symptoms mycophenolate nCoV organ Patient paucity of data PCR testing predict Prospective Study receive recent recipient recipients responses SARS-CoV-2 SARS-COV-2 infection serum analysis solid organ solid organ transplant SOT Spike protein suggested the spike protein to define vaccination Vaccine vaccine doses were recorded [DOI] 10.1016/j.healun.2022.01.005 PMC 바로가기 [Article Type] Article
Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysisReview Published on 2022-03-312023-06-16 Journal: The Journal of Headache and Pain [Category] MERS, SARS, [키워드] adverse event BNT162b2 ChAdOx1 COVID-19 headache SARS-CoV-2 vaccination [DOI] 10.1186/s10194-022-01400-4 PMC 바로가기 [Article Type] Review
BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era델타 시대 스코틀랜드에서 BNT162b2 및 ChAdOx1 nCoV-19 예방 접종, SARS-CoV-2 감염 및 COVID-19 입원 발생Article Published on 2022-03-262022-09-11 Journal: Journal of Global Health [Category] SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age association B.1.617.2 BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 cohort analysis comparable condition coronavirus Coverage COVID-19 COVID-19 hospitalisation defined Delta delta variant dominant dose enhanced Follow-up group Hospital admission Hospital admissions hospitalisation hospitalisations hospitalised incidence incidence rate incidence rates individuals Infection much lower National Older age outcomes performed platform population level positive reduction in SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections severe acute respiratory syndrome Coronavirus severe COVID-19 stratified the SARS-CoV-2 vaccination Vaccination Status Vaccinations Vaccine [DOI] 10.7189/jogh.12.05008 PMC 바로가기 [Article Type] Article
Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient백신 유발 면역 혈전성 혈소판 감소증에서 대부분의 항-PF4 항체는 일시적입니다.Observational Study Published on 2022-03-242022-09-12 Journal: Blood [Category] Fulltext, MERS, 임상, 진단, [키워드] Ad26.COV2-S adenovirus vector vaccine antibodies antibody antiplatelet ChAdOx1 changes in COVID-19 COVID-19 vaccine dose enzyme functional IgG immune immunoassay Immunoglobulin increase in median median time MOST mRNA optical Patient patients PF4 reactivity receive second vaccination thrombotic Thrombotic complications triggered vaccination against COVID-19 [DOI] 10.1182/blood.2021014214 PMC 바로가기 [Article Type] Observational Study